Article
Lipid lowering alone fails to limit atherosclerosis progression and neutrophilic inflammation in middle-aged mice
2025-11-05
Abstract excerpt
While cholesterol lowering remains the cornerstone therapy for atherosclerosis and prevention of major adverse cardiovascular events, 33–50% of individuals on lipid-lowering therapy continue to exhibit elevated inflammation. Middle age (MA) represents a critical window for disease acceleration, underscoring a need to better understand non-resolving inflammation in this time frame. We rendered young (2 months) and...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bed28a74-b44d-5c6d-863c-77a2ce54fba3
- DOI
- 10.1101/2025.11.04.686598
